Cabergoline

Cabergoline: Comprehensive Patient Information

Basic Product Information

Mechanism of Action

For patients: Cabergoline works mainly by reducing the amount of the hormone prolactin in your body. It does this by acting on certain brain pathways (dopamine receptors) to stop your body from making too much prolactin—important for conditions where excess prolactin can cause symptoms such as irregular periods, infertility, or unwanted lactation.

For healthcare professionals: Cabergoline is a long-acting selective dopamine D2 receptor agonist, with high affinity for D2 receptors on lactotroph cells in the pituitary, inhibiting prolactin secretion in a dose-dependent manner. It has a slow dissociation rate, explaining its extended duration of action, and minimal interaction with D1, α1, α2, β-adrenergic or serotonin receptors.

Pharmacokinetics

• Absorption: Well absorbed orally; peak plasma levels 2–3 hours post-dose.
• Metabolism: Extensive hepatic (liver) metabolism; mainly via hydrolysis of the acylurea bond; minimal CYP enzyme involvement.
• Elimination: Elimination half-life is 63–109 hours (often longer in hyperprolactinaemic patients); most excreted in faeces, ~20% in urine.
• Duration of Action: 1–2 weeks for prolactin suppression post-dose; allowing for weekly or twice-weekly dosing in most cases.

Everyday Use and Best Practices

Cabergoline is typically prescribed to treat conditions involving high prolactin levels—such as prolactin-secreting pituitary tumours (prolactinomas), menstrual disorders, and in some cases, to help suppress lactation. In Parkinson's disease, higher doses are sometimes used (Cabaser®), although this is less frequent in Australia.

Typical Dosage:

• Prolactinomas/Hyperprolactinaemia: Start with 0.25 mg twice weekly. Dose is adjusted slowly (every 4 weeks), usually up to a maximum of 1–2 mg/week; some patients may need more.
• Suppression of Lactation: Single dose of 1 mg (can be given as 0.5 mg twice in 24 hours).
• Parkinson’s Disease: Higher doses (rare in AU, specialist setting only): typically initiated at 0.5 mg/day and increased gradually under close monitoring.

Tablets can be broken to achieve the exact prescribed dose if needed. Always follow the exact instructions given by your doctor or pharmacist.

Cabergoline is often used long-term, and patients may require ongoing monitoring (e.g., blood prolactin levels, echocardiography for cardiac function in high-dose or long-term cases).

Morning vs Evening Dosing

Cabergoline can be taken either in the morning or evening. Some patients find it causes nausea, especially at first; in these cases, taking it just before bedtime may reduce stomach upset. Others prefer taking it in the morning with breakfast to help remember. Consistency is key—choose a time you can stick to regularly.

• Morning advantages: Reduces risk of insomnia, fits with a typical medication routine.
• Evening advantages: May help minimise nausea; easier if you have side effects early in treatment.

If you miss a dose, take it as soon as you remember unless it's almost time for your next scheduled dose. Never double up.

Taking with Food or on an Empty Stomach

You may take Cabergoline with or without food. Some people find it gentler on the stomach if taken with a light meal, especially at the start. There is no strong interaction with typical English/Australian foods. If you often have a cup of tea or coffee in the morning, that is also generally safe, but avoid excessive caffeine if you are experiencing stomach upset.

Interaction Warnings (Food, Alcohol, Medications)

Indications

Dosing Guidelines by Indication and Patient Age

Doses must be individualised. Please follow the physician’s directions and consult your health provider before making any changes.

Safety Profile and Side Effects

Cabergoline is generally well tolerated at standard doses, but can cause side effects. Report any concerns to your doctor or pharmacist.

Long-term use (especially in high doses as in Parkinson’s) is linked to increased risk of heart valve problems—your doctor may monitor your heart (echocardiography) as needed.

Proper Use Guidelines

• Always take cabergoline as prescribed—never increase your dose without medical advice.
• Try to take it at the same time(s) each week for best results.
• If you experience nausea, try splitting the dose or taking with meals.
• Inform your doctor about all other prescription, over-the-counter, and herbal medicines you are taking.
• Do not stop taking cabergoline suddenly; always follow your doctor’s plan to reduce or stop the medicine if necessary.
• Attend all recommended blood tests and cardiac monitoring appointments, especially if on long-term or high-dose treatment.
• Store tablets below 25°C; protect from moisture, and keep out of reach of children.

Alternative Treatment Options (PBS/Medicare Reimbursed)

• Bromocriptine: An older dopamine agonist, also listed on the PBS for similar conditions. (Pros: longer safety history, cons: more frequent dosing and often more nausea)
• Quinagolide: Occasionally considered, but less frequently used and not always available in Australia.
• Non-drug approaches: Surgery or radiotherapy for pituitary tumours not responding to medical therapy.
• Observation or 'watch-and-wait': For mild prolactin elevation or microadenomas in select cases.

Choice of treatment depends on clinical situation, tolerability, and individual patient needs. Discuss alternatives with your endocrinologist or neurologist.

Legal, Registration, and Reimbursement Status in Australia

• TGA registration: Cabergoline is approved by the Therapeutic Goods Administration (TGA) in Australia for the management of hyperprolactinaemia, prolactinomas, suppression of postpartum lactation, and Parkinson’s disease (specialist use).
• PBS listing: Cabergoline is available on the Pharmaceutical Benefits Scheme (PBS) for some indications (not all specialist uses may be covered—check with your doctor or local pharmacist).
• Prescription-only (Schedule 4): Must be supplied on a valid prescription from a doctor registered in Australia.
• Reimbursement: For eligible conditions only; co-payment applies; for most brands, concessional and general patient rates are available under the PBS.

Latest Research and Clinical Guidance (2022–2025)

• Current Endocrine Society guidelines (2022–2023) confirm cabergoline as first-line therapy for most patients with prolactinomas due to higher efficacy and improved tolerability compared to older dopamine agonists (e.g., bromocriptine).
• Recent Australian data (2023) suggest most patients require long-term, low-dose therapy and that monitoring for cardiac and psychiatric side effects remains important, especially in elderly or high-dose users. (Brown TJ, et al. "Outcomes of Cabergoline Therapy in an Australian Prolactinoma Cohort," Endocrine Practice, 2023).
• The Australian Prescriber notes that cabergoline is well-tolerated and should be titrated slowly to avoid adverse effects (Australian Medicines Handbook 2024).
• Research in 2024 is examining lower dosages and possible extended dosing intervals to further minimise long-term risks. Large-scale studies continue to support ongoing monitoring protocols for high-risk patients (especially for heart valve screening).

Availability and Delivery

*PBS prices indicative. Actual price may vary by pharmacy; private (non-PBS) prices may be higher. Delivery times may vary by provider and region (Tasmania, WA, NT: allow extra days).

Frequently Asked Questions (FAQ)

1. How long will I need to take cabergoline?
   For prolactinomas and chronic conditions, treatment may be long-term (months to years), but some patients eventually reduce or stop after hormone levels normalise. Never stop except on doctor’s advice.
2. Can I drink alcohol while taking cabergoline?
   Modest alcohol intake is not strictly prohibited, but as cabergoline can cause dizziness and low blood pressure, it is best to avoid or limit alcohol, especially early in treatment.
3. Are there foods I should avoid?
   No foods need to be strictly avoided. You may take cabergoline with or without food, depending on stomach tolerance. There are no major interactions with typical Australian/English meals.
4. What should I do if I miss a dose?
   Take it as soon as you remember unless it is near your next scheduled dose. Do not double the dose. If unsure, ask your pharmacist or doctor.
5. What monitoring is required?
   Blood tests for prolactin, periodic heart (valve) checks with echocardiogram for long-term/high-dose use. Your doctor will advise on a regular schedule.

Always consult your pharmacist, GP, or specialist for personalised advice and before making any changes to your medication routine.